Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07701993 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Name: A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) — clinical trial record (NCT07701993)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NEBULA-1

StatusRecruiting

PhasePhase 3

SponsorGlaxoSmithKline

Started2026-07-22

View on ClinicalTrials.gov ↗

This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.

Amendment history 1 change detected by DataLookout

2026-08-06

Recruitment opened

Trial Details

NCT Number	NCT07701993
Lead Sponsor	GlaxoSmithKline
Conditions	Metabolic Dysfunction-associated Steatohepatitis
Enrollment	1,740 participants
Start Date	2026-07-22
Primary Completion	2033-07-27 (estimated)
Study Completion	2033-08-24 (estimated)
Updated on ClinicalTrials.gov	2026-08-05